Technical Analysis for SLRN - Acelyrin Inc.

Grade Last Price % Change Price Change
F 4.39 -5.18% -0.24
SLRN closed down 5.18 percent on Friday, May 17, 2024, on 60 percent of normal volume.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Gapped Up Strength -7.38%
Up 3 Days in a Row Strength -7.38%
Boomer Sell Setup Bearish Swing Setup -7.19%
Earnings Movers Other -7.19%
Gapped Up Strength -7.19%
1,2,3 Retracement Bearish Bearish Swing Setup -6.40%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -6.40%
Earnings Movers Other -6.40%
Inside Day Range Contraction -6.40%

   Recent Intraday Alerts

Alert Time
Down 5% 1 day ago
Possible NR7 1 day ago
60 Minute Opening Range Breakdown 2 days ago
Down 3% 2 days ago
Fell Below 20 DMA 2 days ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Acelyrin Inc. Description

ACELYRIN, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Drugs Monoclonal Antibodies Uveitis Psoriatic Arthritis Hidradenitis Suppurativa Thyroid Eye Disease Chronic Urticaria Duligotuzumab

Is SLRN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 29.88
52 Week Low 4.14
Average Volume 1,241,601
200-Day Moving Average 10.14
50-Day Moving Average 5.81
20-Day Moving Average 4.51
10-Day Moving Average 4.65
Average True Range 0.33
RSI (14) 33.77
ADX 31.69
+DI 12.76
-DI 21.95
Chandelier Exit (Long, 3 ATRs) 4.18
Chandelier Exit (Short, 3 ATRs) 5.13
Upper Bollinger Bands 4.97
Lower Bollinger Band 4.06
Percent B (%b) 0.36
BandWidth 20.16
MACD Line -0.29
MACD Signal Line -0.39
MACD Histogram 0.102
Fundamentals Value
Market Cap 427.32 Million
Num Shares 97.3 Million
EPS -5.06
Price-to-Earnings (P/E) Ratio -0.87
Price-to-Sales 0.00
Price-to-Book 1.09
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.86
Resistance 3 (R3) 4.90 4.79 4.78
Resistance 2 (R2) 4.79 4.67 4.77 4.75
Resistance 1 (R1) 4.59 4.60 4.54 4.55 4.73
Pivot Point 4.48 4.48 4.45 4.46 4.48
Support 1 (S1) 4.28 4.36 4.23 4.24 4.05
Support 2 (S2) 4.17 4.29 4.15 4.03
Support 3 (S3) 3.97 4.17 4.00
Support 4 (S4) 3.93